Cargando…
Quantitative muscle MRI to follow up late onset Pompe patients: a prospective study
Late onset Pompe disease (LOPD) is a slow, progressive disorder characterized by skeletal and respiratory muscle weakness. Enzyme replacement therapy (ERT) slows down the progression of muscle symptoms. Reliable biomarkers are needed to follow up ERT-treated and asymptomatic LOPD patients in clinica...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6052002/ https://www.ncbi.nlm.nih.gov/pubmed/30022036 http://dx.doi.org/10.1038/s41598-018-29170-7 |
_version_ | 1783340586834591744 |
---|---|
author | Figueroa-Bonaparte, Sebastian Llauger, Jaume Segovia, Sonia Belmonte, Izaskun Pedrosa, Irene Montiel, Elena Montesinos, Paula Sánchez-González, Javier Alonso-Jiménez, Alicia Gallardo, Eduard Illa, Isabel Díaz-Manera, Jordi |
author_facet | Figueroa-Bonaparte, Sebastian Llauger, Jaume Segovia, Sonia Belmonte, Izaskun Pedrosa, Irene Montiel, Elena Montesinos, Paula Sánchez-González, Javier Alonso-Jiménez, Alicia Gallardo, Eduard Illa, Isabel Díaz-Manera, Jordi |
author_sort | Figueroa-Bonaparte, Sebastian |
collection | PubMed |
description | Late onset Pompe disease (LOPD) is a slow, progressive disorder characterized by skeletal and respiratory muscle weakness. Enzyme replacement therapy (ERT) slows down the progression of muscle symptoms. Reliable biomarkers are needed to follow up ERT-treated and asymptomatic LOPD patients in clinical practice. In this study, 32 LOPD patients (22 symptomatic and 10 asymptomatic) underwent muscle MRI using 3-point Dixon and were evaluated at the time of the MRI with several motor function tests and patient-reported outcome measures, and again after one year. Muscle MRI showed a significant increase of 1.7% in the fat content of the thigh muscles in symptomatic LOPD patients. In contrast, there were no noteworthy differences between muscle function tests in the same period of time. We did not observe any significant changes either in muscle MRI or in muscle function tests in asymptomatic patients over the year. We conclude that 3-point Dixon muscle MRI is a useful tool for detecting changes in muscle structure in symptomatic LOPD patients and could become part of the current follow-up protocol in daily clinics. |
format | Online Article Text |
id | pubmed-6052002 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-60520022018-07-23 Quantitative muscle MRI to follow up late onset Pompe patients: a prospective study Figueroa-Bonaparte, Sebastian Llauger, Jaume Segovia, Sonia Belmonte, Izaskun Pedrosa, Irene Montiel, Elena Montesinos, Paula Sánchez-González, Javier Alonso-Jiménez, Alicia Gallardo, Eduard Illa, Isabel Díaz-Manera, Jordi Sci Rep Article Late onset Pompe disease (LOPD) is a slow, progressive disorder characterized by skeletal and respiratory muscle weakness. Enzyme replacement therapy (ERT) slows down the progression of muscle symptoms. Reliable biomarkers are needed to follow up ERT-treated and asymptomatic LOPD patients in clinical practice. In this study, 32 LOPD patients (22 symptomatic and 10 asymptomatic) underwent muscle MRI using 3-point Dixon and were evaluated at the time of the MRI with several motor function tests and patient-reported outcome measures, and again after one year. Muscle MRI showed a significant increase of 1.7% in the fat content of the thigh muscles in symptomatic LOPD patients. In contrast, there were no noteworthy differences between muscle function tests in the same period of time. We did not observe any significant changes either in muscle MRI or in muscle function tests in asymptomatic patients over the year. We conclude that 3-point Dixon muscle MRI is a useful tool for detecting changes in muscle structure in symptomatic LOPD patients and could become part of the current follow-up protocol in daily clinics. Nature Publishing Group UK 2018-07-18 /pmc/articles/PMC6052002/ /pubmed/30022036 http://dx.doi.org/10.1038/s41598-018-29170-7 Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Figueroa-Bonaparte, Sebastian Llauger, Jaume Segovia, Sonia Belmonte, Izaskun Pedrosa, Irene Montiel, Elena Montesinos, Paula Sánchez-González, Javier Alonso-Jiménez, Alicia Gallardo, Eduard Illa, Isabel Díaz-Manera, Jordi Quantitative muscle MRI to follow up late onset Pompe patients: a prospective study |
title | Quantitative muscle MRI to follow up late onset Pompe patients: a prospective study |
title_full | Quantitative muscle MRI to follow up late onset Pompe patients: a prospective study |
title_fullStr | Quantitative muscle MRI to follow up late onset Pompe patients: a prospective study |
title_full_unstemmed | Quantitative muscle MRI to follow up late onset Pompe patients: a prospective study |
title_short | Quantitative muscle MRI to follow up late onset Pompe patients: a prospective study |
title_sort | quantitative muscle mri to follow up late onset pompe patients: a prospective study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6052002/ https://www.ncbi.nlm.nih.gov/pubmed/30022036 http://dx.doi.org/10.1038/s41598-018-29170-7 |
work_keys_str_mv | AT figueroabonapartesebastian quantitativemusclemritofollowuplateonsetpompepatientsaprospectivestudy AT llaugerjaume quantitativemusclemritofollowuplateonsetpompepatientsaprospectivestudy AT segoviasonia quantitativemusclemritofollowuplateonsetpompepatientsaprospectivestudy AT belmonteizaskun quantitativemusclemritofollowuplateonsetpompepatientsaprospectivestudy AT pedrosairene quantitativemusclemritofollowuplateonsetpompepatientsaprospectivestudy AT montielelena quantitativemusclemritofollowuplateonsetpompepatientsaprospectivestudy AT montesinospaula quantitativemusclemritofollowuplateonsetpompepatientsaprospectivestudy AT sanchezgonzalezjavier quantitativemusclemritofollowuplateonsetpompepatientsaprospectivestudy AT alonsojimenezalicia quantitativemusclemritofollowuplateonsetpompepatientsaprospectivestudy AT gallardoeduard quantitativemusclemritofollowuplateonsetpompepatientsaprospectivestudy AT illaisabel quantitativemusclemritofollowuplateonsetpompepatientsaprospectivestudy AT quantitativemusclemritofollowuplateonsetpompepatientsaprospectivestudy AT diazmanerajordi quantitativemusclemritofollowuplateonsetpompepatientsaprospectivestudy |